Research Triangle Park, N.C.-based TransEnterix said it expects to post sales of $6.0 million to $6.3 million for the three months ended ended June 30, 2018, up 300% to 320% compared with Q2 2017. Analysts on The Street were looking for sales of $5.4 million.
TransEnterix also revealed another sale of its Senhance device via distributor for Europe, Middle East, & Africa last month, taking the June sales tally to four systems.
“We had a strong second quarter as we continued to drive sales of Senhance globally while at the same time making significant progress towards our 2018 goals, including the expansion of Senhance’s indications for use and portfolio of instruments,” said Todd M. Pope, President and CEO at TransEnterix. “We look forward to continuing to build upon the momentum we developed during the first half of the year to drive the widespread adoption of Senhance.”
TransEnterix said it had about $98 million in cash & equivalents as of June 30.
TRXC shares were up 8.7% to $4.74 apiece today in pre-market trading.
On December 11-12,DeviceTalks West is taking over Orange County's medtech industry with one of the most anticipated conferences of the winter, bringing you the best and brightest minds in the industry.
Dr. Robert Greenberg, Executive Chairman, Alfred E. Mann Foundation
Gary Guthart, President and Chief Executive Officer, Intuitive Surgical
Reggie Groves, CEO, REVA Medical
Use code KEYNOTE to save an additional 10%.